Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

147.27 -1.26 (-0.85%)
Streaming Delayed Price Updated: 10:01 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Johnson & Johnson Announces Final Exchange Ratio of 8.0324 in Split-Off of Kenvue Inc.
From Johnson & Johnson
Via Business Wire
Johnson & Johnson (NYSE: JNJ) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
5 Best Stocks to Buy in a Bear Market
Want income-producing assets and stable stocks? Look for stocks with stable cash flow in rock-solid industries for the best stocks to buy in a bear market. 
Via MarketBeat
Topics Economy
Exposures Economy
3 Stocks to Play the Recovery in Digital Advertising
The slowdown in digital advertising triggered many technology stocks to sell off, notably social media platforms like Snap Inc. (NASDAQ: SNAP). However, a 
Via MarketBeat
Topics Earnings
Exposures Financial
Johnson & Johnson (NYSE: JNJ) Highlighted for Surprising Price Action
Via Investor Brand Network
Healthcare Week boon for medical industry
From HKTDC
Via ACN Newswire
Asia Summit on Global Health gathers 90+ global elites
From HKTDC
Via ACN Newswire
Johnson & Johnson to Participate in the 2023 Wells Fargo Securities Healthcare Conference
From Johnson & Johnson
Via Business Wire
Rising Dividend Make Zoetis a Doggone Winner
Investors that typically focus on other large cap pharmaceutical plays may wish to consider an alternative bet on pets with shares of Zoetis. 
Via MarketBeat
Nachawati Law Group Trial Lawyers Renew Commitment to Cancer Victims After Judge’s Rejection of Johnson & Johnson’s Proposed $8.9B Settlement
From Nachawati Law Group
Via Business Wire
3 Consumer Discretionary Stocks That Still Have Pricing Power
Pricing power fuels earnings growth and here are three consumer discretionary stocks that have recently given investors confirmation of their pricing power 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement
From Kenvue Inc.
Via Business Wire
Johnson & Johnson Launches Exchange Offer for Separation of Kenvue Inc.
From Johnson & Johnson
Via Business Wire
MarketBeat Week in Review – 7/17 - 7/21
Investor sentiment remains strong but upcoming tech earnings and an expected interest rate hike may provide more clarity on the short-term outlook for stocks 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Johnson & Johnson's Inflection Point: What it Means for Investors
Johnson & Johnson stock and the company show signs of strength and growth while offering value and yield relative to its peer Abbott Laboratories. 
Via MarketBeat
Exposures COVID-19
Johnson & Johnson Reports Q2 2023 Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the UBS MedTech, Tools and Genomics Summit
From Johnson & Johnson
Via Business Wire
Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy
Inspire Medical Systems has surged nearly 15% since its breakout, driven by positive Q1 results and FDA approvals. Analysts have a "buy" rating on the stock. 
Via MarketBeat
Exposures Product Safety
OnderLaw Lauds Revolutionary Drug Combination that Offers Hope for Women with Ovarian Cancer
June 23, 2023 -- Drug Combination Shows Special Promise to Those Diagnosed with Johnson & Johnson Talc-Related Ovarian Cancer 
Via 24-7 Press Release
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer. 
Via MarketBeat
Will Cava's Successful Debut Raise Hope For Reviving IPO Market?
Cava's strong IPO performance suggests a warming trend in the market for new public debuts. However, several eagerly anticipated offerings remain on hold. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Filariasis Market and Epidemiology 2032: Treatment Market, Therapies, FDA Approvals, and Companies by DelveInsight | Johnson & Johnson, Pfizer, Eisai Co Ltd, Atra Pharmaceuticals, AbbVie, Novartis
Via AB Newswire
Exposures Product Safety
Ophthalmoplegia Market expected to rise | Companies – Abbott, Novartis AG, ZEISS International, Valeant Pharmaceuticals International, ALLERGAN, Johnson & Johnson, expected to drive market
Via AB Newswire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
From Johnson & Johnson
Via Business Wire
Smokeless Tobacco Treatment Market to See Booming Growth : Novartis, Pfizer, Johnson & Johnson, Cambrex
Smokeless Tobacco Treatment Comprehensive Study by Type (Keratosis Treatment, Addiction Treatment, Disease Treatment), Application (Hospitals & Clinics, Academic & Research Organizations, Pharmacies),... 
Via SBWire
Exposures Climate
2022 R&D Spending and Intensity Benchmarks
VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D... 
Via PRLog
Topics Supply Chain
Exposures Supply Chain
Will Dividends Take Center Stage In The Second Half Of 2023?
The NYSE Composite's sideways trade since early 2021 could be a warning sign, suggesting that a shift toward dividend strategies may be prudent. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tampons Market Is Booming Worldwide : Johnson & Johnson, Kimberly-Clark, Ontex, Unicharm
Tampons Comprehensive Study by Type (Radially Wound Pledget, Rectangular/Square Pad), Distribution Channel (Online, Offline (Supermarkets/Hypermarkets, Independent Retailers, Specialty Stores, Drug... 
Via SBWire
Exposures Textiles
Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea 
Via MarketBeat
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.